You are here Home Resources and guidance Sponsors BeiGene AUS Pty Ltd Regulatory activities for this sponsor. Listen Print Share LinkedIn (Twitter) Facebook Email Loading... Type (-) Designation or determination (3) Prescription medicine registration (8) Australian public assessment report (AusPar) (4) Prescription medicine decision summary (3) Cancellation by sponsor (1) Date 2023 (1) 2021 (1) 2020 (1) Search Filters applied:Designation or determinationClear all Sponsor content3 result(s) found, displaying 1 to 3 Notice for tislelizumab (Beigene Aus Pty Ltd) 23 October 2023 Designation or determination Orphan drug Notice for zanubrutinib (BeiGene AUS Pty Ltd) 20 September 2021 Designation or determination Provisional approval Notice for zanubrutinib (BeiGene Aus Pty Ltd) 17 June 2020 Designation or determination Provisional approval
Notice for tislelizumab (Beigene Aus Pty Ltd) 23 October 2023 Designation or determination Orphan drug
Notice for zanubrutinib (BeiGene AUS Pty Ltd) 20 September 2021 Designation or determination Provisional approval
Notice for zanubrutinib (BeiGene Aus Pty Ltd) 17 June 2020 Designation or determination Provisional approval